Sorry for the delay. Time zone is 7hrs behind over here.
I think Philm answered most of your questions.
I didnt mean to create fear. If i did I apologise. I have a reasonably large holding of IHL, with both heads and oppies. In fact after some recent oppie purchases I hold more of this than that other share of mine you refer to.
There is always risk with spec stocks. You can mitigate this with research, who is running the company? Where does their product fit in the market? What is their MC like compared to peers? What else is in the pipeline etc. So I think when this is all considered we are in a space. But their is still risk until the product is commercialised.
The timeline from pre clinical to end of trial can be a long one. That other share that I hold has a few pre clinical cancer products that have pre clinical for almost two years. One trial that commenced early to mid last year is forcast to give results by the end of next month. So it all needs time. And that is normal.
We should expect an announcement that approval for trial is given. Then that they recruiting for the trial, and then when first patient is dosed. So a few announcements yet until we are underway.
Also I think someone else has already mentioned that the oil sales dont seem to be fully factored into the price yet. I would expect some movement of share price after the next quarterly if they keep the growth rate of this like the last quarter.
IHL Price at posting:
7.2¢ Sentiment: Hold Disclosure: Held
